https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-10-02 / Front Immunol 2023;14:1241949
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-10-02 / Front Immunol 2023;14:12419492023-10-02 00:00:002023-10-02 00:00:00Targeting the pericyte antigen DLK1 with an alpha type-1 polarized dendritic cell vaccine results in tumor vascular modulation and protection against colon cancer progression
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-09-04 / Cancer Immunol Immunother 2023 Nov;72(11):3727-3738
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-09-04 / Cancer Immunol Immunother 2023 Nov;72(11):3727-37382023-09-04 00:00:002023-09-04 00:00:00Combination therapy with dendritic cell loaded-exosomes supplemented with PD-1 inhibition at different time points have superior antitumor effect in hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-09-01 / Clin Exp Med 2023 Dec;23(8):4431-4447
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-09-01 / Clin Exp Med 2023 Dec;23(8):4431-44472023-09-01 00:00:002023-09-01 00:00:00Breast cancer immunotherapy: a comprehensive review
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-08-28 / Cells 2023 Aug;12(17)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-08-28 / Cells 2023 Aug;12(17)2023-08-28 00:00:002023-08-28 00:00:00Cancer Vaccine Therapeutics: Limitations and Effectiveness-A Literature Review
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-08-12 / Vaccines (Basel) 2023 Aug;11(8)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-08-12 / Vaccines (Basel) 2023 Aug;11(8)2023-08-12 00:00:002023-08-12 00:00:00A Comprehensive Review on Cancer Vaccines and Vaccine Strategies in Hepatocellular Carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-08-11 / Int Immunopharmacol 2023 Oct;123:110722
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-08-11 / Int Immunopharmacol 2023 Oct;123:1107222023-08-11 00:00:002023-08-11 00:00:00Adenovirus-assembled DC vaccine induces dual-targeting CTLs for tumor antigen and adenovirus to eradicate tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-07-31 / Cancers (Basel) 2023 Jul;15(15)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-07-31 / Cancers (Basel) 2023 Jul;15(15)2023-07-31 00:00:002023-07-31 00:00:00Clinical Applications of Immunotherapy for Recurrent Glioblastoma in Adults
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-07-28 / Transl Cancer Res 2023 Aug;12(8):2224-2228
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-07-28 / Transl Cancer Res 2023 Aug;12(8):2224-22282023-07-28 00:00:002024-04-17 15:08:24Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-07-15 / J Immunol 2023 Jul;211(2):219-228
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-07-15 / J Immunol 2023 Jul;211(2):219-2282023-07-15 00:00:002024-01-16 09:10:27Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-07-01 / Life (Basel) 2023 Jul;13(7)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-07-01 / Life (Basel) 2023 Jul;13(7)2023-07-01 00:00:002023-07-01 00:00:00Potential of Personalized Dendritic Cell-Based Immunohybridoma Vaccines to Treat Prostate Cancer
